Who owns Mirum Pharmaceuticals, Inc. (MAXM)? Elite investor 13F holders
4 tracked elite investors reported holding Mirum Pharmaceuticals, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Polen Capital Management, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | MIRUM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 51766598.00 USD | 442185.000000 | Shares | reduce | Original filing |
| D.E. Shaw | MIRUM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3263795.00 USD | 27879.000000 | Shares | reduce | Original filing |
| Polen Capital Management | MIRUM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 2446646.00 USD | 20899.000000 | Shares | add | Original filing |
| Gotham Asset Management | MIRUM PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 279212.00 USD | 2385.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.